ImmunityBio, Inc. (NASDAQ:IBRX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of ImmunityBio, Inc. (NASDAQ:IBRX) have received an average recommendation of “Moderate Buy” from the seven research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $14.40.

A number of equities research analysts have issued reports on IBRX shares. BTIG Research began coverage on ImmunityBio in a research note on Thursday, March 12th. They issued a “buy” rating and a $13.00 price target for the company. Jefferies Financial Group boosted their price objective on ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Piper Sandler reaffirmed an “overweight” rating and issued a $12.00 price objective (up from $7.00) on shares of ImmunityBio in a research note on Wednesday, March 4th. HC Wainwright increased their target price on ImmunityBio from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, February 23rd. Finally, D. Boral Capital reissued a “buy” rating and set a $23.00 target price on shares of ImmunityBio in a research note on Monday, March 23rd.

Key ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Independent Data Monitoring Committee says the pivotal randomized BCG‑naïve NMIBC trial is adequately powered and ImmunityBio’s supplemental BLA submission remains on track for 2026 — supports ANKTIVA’s regulatory path. Business Wire: Trial power check & BLA on track
• Positive Sentiment: Regulatory win: ANKTIVA approved in Macau SAR — expands commercial footprint for the lead biologic. MSN: ANKTIVA approval in Macau
• Positive Sentiment: Analyst action: a reported price‑target increase (to $15.10) signals some sell‑side confidence in upside potential. MSN: Price target raised
• Neutral Sentiment: Industry comparison pieces highlight that IBRX’s upside is tied to single‑drug success (ANKTIVA) versus larger peers’ broader pipelines — useful context for risk/reward but not immediate news. Zacks: IBRX vs. Moderna analysis
• Neutral Sentiment: Market note: some premarket commentary reflected the clinical update but also showed intraday volatility — indicates investors are parsing both upside and headline risk. Benzinga: Trial clears power check (and market reaction)
• Negative Sentiment: Major near‑term negative: a flurry of securities‑fraud class actions and investigations were filed/announced by multiple law firms (Rosen, Faruqi & Faruqi, Robbins, Pomerantz, Block & Leviton, Portnoy, Kaplan Fox, etc.) related to activity between Jan 19–Mar 24, 2026; investors face potential litigation costs, distraction, and reputational risk — lead‑plaintiff motions are due (May 26, 2026). PR Newswire: Rosen files class action
• Negative Sentiment: Regulatory/legal pressure amplified by reports of an FDA warning that has put ANKTIVA expectations and valuation in focus — raises execution and approval risk. Yahoo Finance: FDA warning on ANKTIVA

Insider Buying and Selling

In related news, Director Barry J. Simon sold 75,000 shares of the company’s stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $12.01, for a total transaction of $900,750.00. Following the completion of the transaction, the director owned 2,850,821 shares in the company, valued at approximately $34,238,360.21. This represents a 2.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Christobel Selecky sold 25,000 shares of the firm’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 501,967 shares of company stock valued at $4,466,412. Insiders own 69.48% of the company’s stock.

Institutional Trading of ImmunityBio

Several hedge funds have recently bought and sold shares of IBRX. Armistice Capital LLC bought a new position in shares of ImmunityBio during the 2nd quarter valued at about $20,497,000. Heights Capital Management Inc. bought a new stake in shares of ImmunityBio in the third quarter worth about $16,152,000. Vanguard Group Inc. lifted its position in shares of ImmunityBio by 26.8% in the third quarter. Vanguard Group Inc. now owns 27,655,205 shares of the company’s stock worth $68,032,000 after buying an additional 5,837,898 shares in the last quarter. State Street Corp boosted its stake in ImmunityBio by 45.4% during the fourth quarter. State Street Corp now owns 16,455,703 shares of the company’s stock valued at $32,582,000 after buying an additional 5,139,890 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in ImmunityBio by 439.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 6,152,684 shares of the company’s stock valued at $12,182,000 after buying an additional 5,012,001 shares during the last quarter. Hedge funds and other institutional investors own 8.58% of the company’s stock.

ImmunityBio Price Performance

IBRX opened at $7.38 on Friday. The firm has a market cap of $7.59 billion, a P/E ratio of -19.42 and a beta of -0.03. ImmunityBio has a 1-year low of $1.83 and a 1-year high of $12.43. The company has a 50 day simple moving average of $7.68 and a two-hundred day simple moving average of $4.23.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02. The firm had revenue of $38.29 million for the quarter. Equities analysts anticipate that ImmunityBio will post -0.92 earnings per share for the current year.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.